Freeline Therapeutics

Focused on developing innovative gene therapies to treat chronic diseases

Freeline is focused on AAV-based gene therapy targeting the liver. The company’s vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline’s pipeline includes therapeutics to treat haemophilia A and B, Fabry disease, and Gaucher disease.

Status
NASDAQ: FRLN
Year of Investment
2020
Strategy
Life Sciences
Location
London